<DOC>
	<DOCNO>NCT00277160</DOCNO>
	<brief_summary>The purpose study ass pegfilgrastim start first cycle versus secondary prophylaxis neutropenic event ( include neutropenia +/- fever , dose delay , dose reduction , hospitalization ) old patient receive chemotherapy .</brief_summary>
	<brief_title>A Study Primary Prophylaxis With Neulasta ( Pegfilgrastim ) Versus Secondary Prophylaxis After Chemotherapy Elderly Subjects ( &gt; /= 65 Years Old ) With Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<criteria>&gt; /= 65 year old document diagnosis lung , breast , ovarian cancer , NHL schedule receive one 15 standard chemotherapy regimens chemotherapy naive OR receive adjuvant therapy AND/OR one regimen chemotherapy metastatic disease life expectancy least 3 month ECOG performance status &lt; /=2 adequate renal hematologic function inform consent participation study prior study specific procedure know hypersensitivity product administer dose primary prophylactic antibiotic cycle prior radiation therapy within 2 week randomization study plan radiation therapy study participation , except spot radiation bony metastases prior bone marrow stem cell transplant plan receive transplant therapy study participation clinically symptomatic brain metastasis Folstein minimental state exam score &lt; 18 Any premalignant myeloid condition malignancy myeloid characteristic History prior malignancy within last 5 year subject 's original cancer diagnosis list inclusion criterion exception curatively treat basal cell carcinoma , squamous cell carcinoma , situ cervical carcinoma surgically cured malignancy unstable/uncontrolled cardiac condition hypertension active infection subject currently enrol yet complete least 30 day since end investigational device drug trial receive investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>